In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $1.77 in the last session, down -3.28% from day before closing price of $1.83. In other words, the price has decreased by -$3.28 from its previous closing price. On the day, 1.72 million shares were traded. LXRX stock price reached its highest trading level at $1.84 during the session, while it also had its lowest trading level at $1.75.
Ratios:
We take a closer look at LXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.56 and its Current Ratio is at 15.58. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 30, 2024, initiated with a Outperform rating and assigned the stock a target price of $5.
On March 07, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $3.
On August 12, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.Piper Sandler initiated its Overweight rating on August 12, 2022, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 16 ’23 when COATS LONNEL bought 90,000 shares for $1.05 per share. The transaction valued at 94,797 led to the insider holds 914,359 shares of the business.
COATS LONNEL bought 10,000 shares of LXRX for $10,100 on Nov 10 ’23. The Chief Executive Officer now owns 824,359 shares after completing the transaction at $1.01 per share. On Oct 12 ’23, another insider, DEBBANE RAYMOND, who serves as the Director of the company, bought 148,820 shares for $1.03 each. As a result, the insider paid 153,805 and bolstered with 1,340,847 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 435839456 and an Enterprise Value of 186508048. For the stock, the TTM Price-to-Sale (P/S) ratio is 188.68 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at 80.739 whereas that against EBITDA is -1.006.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.73, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -15.40%, while the 200-Day Moving Average is calculated to be 5.81%.
Shares Statistics:
According to the various share statistics, LXRX traded on average about 4.58M shares per day over the past 3-months and 3400770 shares per day over the past 10 days. A total of 244.92M shares are outstanding, with a floating share count of 239.50M. Insiders hold about 2.74% of the company’s shares, while institutions hold 73.74% stake in the company. Shares short for LXRX as of 1713139200 were 20123733 with a Short Ratio of 4.39, compared to 1710460800 on 21345582. Therefore, it implies a Short% of Shares Outstanding of 20123733 and a Short% of Float of 42.169996999999995.
